Please login to the form below
Xeljanz
This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.
Incyte’s JAK inhibitor cream clears second eczema trial
The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for
Latest news
-
Skyrizi, Rinvoq help AbbVie weather Humira slowdown
Meanwhile, selective JAK inhibitor Rinvoq added another $33m from its first approval in rheumatoid arthritis, as it took on market leader Xeljanz (tofacitinib) from Pfizer, which showed the first signs of
-
Vyndaqel a bright spot as Pfizer comes under pressure
The company’s fourth-quarter results saw a 9% drop in revenues to $12.69bn, with breast cancer drug Ibrance (palbociclib) and Xeljanz (tofacitinib) for rheumatoid arthritis both growing but missing ... Ibrance was up 15% to $1.28bn in the quarter,
-
GSK, Pfizer and Sanofi among drugmakers planning price hikes in US
This includes its CDK 4/6 inhibitor Ibrance (palbociclib), which grew by 27% to $1.3bn in the last quarter, and its fast-growing oral JAK inhibitor Xeljanz (tofacitinib).
-
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis
This includes a number of patient organisations who argue that drugs like Rinvoq and Pfizer’s JAK inhibitor Xeljanz (tofacitinib) have created real improvements for people living with the condition.
-
J&J splashes $750m on anti-inflammatory drug bermekimab
As well as facing competition from Cosentyx and Skyrizi, Tremfya also has to contend with Eli Lilly’s IL-17 inhibitor Taltz (ixekizumab) and Pfizer’s oral JAK inhibitor Xeljanz (tofacitinib),
More from news
Approximately 19 fully matching, plus 63 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
JAK inhibitors such as Xeljanz and Rinvoq.
-
20 for 2020 – Five pharma leaders to watch in 2020
to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others.
-
Pharma deals during September 2013
antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
-
Infographic: RA Perceptions
The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
-
Brand leaders in RA will lose market share, predict rheumatologists
JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. . ... The EMA’s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- FDA approves Roche’s Actemra COVID-19 trial
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
